-+ 0.00%
-+ 0.00%
-+ 0.00%
Luye Pharmaceutical announced on the Hong Kong Stock Exchange that Ruoxinlin®, a Class 1 innovative drug independently developed by the company, has been approved by the China Drug Administration to treat generalized anxiety disorder. According to the company's knowledge, this product is the first innovative anti-anxiety chemical drug developed independently in China and has independent intellectual property rights, marking a major breakthrough in the field of treatment in China's original innovative drug. Ruoxinlin® was first approved for marketing in China in November 2022 to treat depression. The generalized anxiety disorder indication approved this time is the second indication obtained by this product in China.
Share
Listen to the news
Luye Pharmaceutical announced on the Hong Kong Stock Exchange that Ruoxinlin®, a Class 1 innovative drug independently developed by the company, has been approved by the China Drug Administration to treat generalized anxiety disorder. According to the company's knowledge, this product is the first innovative anti-anxiety chemical drug developed independently in China and has independent intellectual property rights, marking a major breakthrough in the field of treatment in China's original innovative drug. Ruoxinlin® was first approved for marketing in China in November 2022 to treat depression. The generalized anxiety disorder indication approved this time is the second indication obtained by this product in China.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending